BioSpace News Archive

Clearside Biomedical, Inc. announced that several key poster presentations were delivered on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology 2023 Annual Meeting.

BioCryst Pharmaceuticals, Inc. announced new data from the APeX-S clinical trial, which evaluated oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema, showing sustained reduction in disease burden for patients across multiple subgroups through 96 weeks of treatment.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company) today announced positive interim clinical data from the Phase 1 Dose Exploration stage (three doses, n=15) of the 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD).

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.

Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview.

Medicenna Therapeutics Corp. today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance with the minimum bid price requirement (“Minimum Bid Requirement”) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1).

Tiziana Life Sciences Ltd. today announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference.

Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, unveiled a breakthrough in cell manufacturing that potentially solves one of the biggest hurdles facing cell-based industries: cost-effective, industrial scale cell manufacturing.

Compugen Ltd. today announced that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) annual meeting on June 2-6, 2023, in Chicago, Illinois.

Biomica Ltd. today announced that it has closed a financing round of $20 million.